Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2002-09-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-002-0504-9PMID 12439599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

  2002cited by this paper
• Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.

  2001cited by this paper
• EPR spectroscopic studies of the reduction of chromium(VI) by methanol in the presence of peptides. Formation of long-lived chromium(V) peptide complexes.

  2001cited by this paper
• DNA as a possible target for antitumor ruthenium(III) complexes.

  2000cited by this paper
• Enantiomeric ruthenium(II) complexes binding to DNA: binding modes and enantioselectivity

  2000cited by this paper
• DNA targeted platinum complexes: synthesis, cytotoxicity and DNA interactions of cis-dichloroplatinum(II) complexes tethered to phenazine-1-carboxamides.

  2000cited by this paper
• Antitumor activity of mono- and dimetallic transition metal carborane complexes of Ta, Fe, Co, Mo, or W.

  2000cited by this paper
• Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.

  2000cited by this paper
• Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.

  2000cited by this paper
• Redox pathways in DNA oxidation: kinetic studies of guanine and sugar oxidation by para-substituted derivatives of oxoruthenium(IV).

  2000cited by this paper
• A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.

  2000cited by this paper
• Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

  2000cited by this paper
• Cytotoxicity of copper and cobalt complexes of furfural semicarbazone and thiosemicarbazone derivatives in murine and human tumor cell lines.

  2000cited by this paper
• Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells

  2000cited by this paper
• In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.

  1999cited by this paper
• Sulfoxide Ruthenium Complexes: Non-Toxic Tools for the Selective Treatment of Solid Tumour Metastases

  1999cited by this paper
• Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.

  1999cited by this paper
• Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.

  1999cited by this paper
• Drug control of solid tumour metastases: a critical view.

  1999cited by this paper
• Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.

  1999cited by this paper
• Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

  1998cited by this paper
• Histidine-containing dipeptides as endogenous regulators of the activity of sarcoplasmic reticulum Ca-release channels.

  1997cited by this paper
• Treatment of residual metastases with Na[trans-RuCl4(DMSO)lm] and ruthenium uptake by tumor cells

  1996cited by this paper
• Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by tetramethylammonium hydroxide.

  1992cited by this paper
• Cytostatic and antitumour properties of a new series of Pt (II) complexes with cyclopentylamine.

  1987cited by this paper
• Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.

  1986cited by this paper
• The binding of Ruthenium red to tubulin.

  1985cited by this paper
• On the synthesis, cytostatic and antitumor properties of new Pt(II) and Pt(IV) complexes with chloroanilines.

  1985cited by this paper
• Cellular binding and/or uptake of nickel(II) ions.

  1984cited by this paper
• Actions of cis-diamminedichloroplatinum on cell surface nucleic acids in cancer cells as determined by cell electrophoresis techniques.

  1982cited by this paper
• Manual of pharmacologic calculations with computer programs

  1982cited by this paper
• Ultrastructural study of membrane glycocalyx in primary and metastatic human and rat mammary carcinoma

  1981cited by this paper
• RAPID, SIMULTANEOUS MEASUREMENT OF DNA, PROTEIN, AND CELL VOLUME IN SINGLE CELLS FROM LARGE MAMMALIAN CELL POPULATIONS

  1973cited by this paper
• Amino acid metabolism in mammalian cell cultures.

  1959cited by this paper

• Synthesis, spectroscopic, computational, molecular docking, antidiabetic(in vitro & in vivo) DNA and BSA interaction studies of ruthenium(II) carboxylate complexes.

  2024cites this paper
• Versatile impact of serum proteins on ruthenium(II) polypyridyl complexes properties - Opportunities and obstacles.

  2019cites this paper
• Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

  2017cites this paper
• The Microbiology of Ruthenium Complexes.

  2017cites this paper
• Ruthenium Anticancer Agents—From Cisplatin Analogues to Rational Drug Design

  2017cites this paper
• Comparison of KP1019 and NAMI-A in tumour-mimetic environments.

  2016cites this paper
• Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.

  2015cites this paper
• Incorporating ruthenium into advanced drug delivery carriers – an innovative generation of chemotherapeutics

  2015cites this paper
• Theoretical and experimental studies of phenol oxidation by ruthenium complex with N,N,N-tris(benzimidazol-2yl-methyl)amine

  2015cites this paper
• Ruthenium-Nitrosyl Complexes with Glycine, l-Alanine, l-Valine, l-Proline, d-Proline, l-Serine, l-Threonine, and l-Tyrosine: Synthesis, X-ray Diffraction Structures, Spectroscopic and Electrochemical Properties, and Antiproliferative Activity

  2014cites this paper
• NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.

  2014cites this paper
• EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.

  2013cites this paper
• Next-generation metal anticancer complexes: multitargeting via redox modulation.

  2013cites this paper
• CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.

  2012cites this paper
• Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.

  2012cites this paper
• Synthesis, molecular structure and spectral analysis: DFT–TDDFT computational study of ruthenium complex of tetradentate N,N′-bis(benzimidazole-2yl-ethyl)-ethylenediamine

  2011cites this paper
• Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA.

  2011cites this paper
• Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.

  2010cites this paper
• Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.

  2010cites this paper
• Cerebrosides with antiproliferative activity from Euphorbia peplis L.

  2010cites this paper
• Synthesis, structure, and electrochemistry of mer[RuCl3(DMSO–S)(DMSO–O)(py)]

  2009cites this paper
• Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate.

  2009cites this paper
• Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.

  2007cites this paper
• Synthesis and biological properties of new α-methylene-γ-butyrolactones and α,β-unsaturated δ-lactones

  2006cites this paper
• Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy

  2006cites this paper
• Ruthenium(III) maltolato-nitroimidazole complexes: synthesis and biological activity.

  2006cites this paper
• Ruthenium complexes as anticancer agents.

  2006cites this paper
• Synthesis and biological properties of new alpha-methylene-gamma-butyrolactones and alpha,beta-unsaturated delta-lactones.

  2006cites this paper
• Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells

  2005cites this paper
• Ruthenium antimetastatic agents.

  2004cites this paper
• Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

  2004cites this paper
• Ruthenium anticancer drugs.

  2004cites this paper
• Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin

  2003cites this paper
• Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.

  2003cites this paper